<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103684</url>
  </required_header>
  <id_info>
    <org_study_id>LDVHDSE</org_study_id>
    <nct_id>NCT04103684</nct_id>
  </id_info>
  <brief_title>Steroids in Treatment of Viral Encephalitis</brief_title>
  <official_title>Low Dose Versus High Dose Steroids in Treatment of Viral Encephalitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      acute viral encephalitis is used to describe restricted CNS involvement (namely, involvement
      of the brain, sparing the meninges)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Viral encephalitis is a medical emergency The spectrum of brain involvement and the prognosis
      are dependent mainly on the specific pathogen and the immunological state of the host.

      Although specific therapy is limited to only several viral agents, correct immediate
      diagnosis and introduction of symptomatic and specific therapy has a dramatic influence upon
      survival and reduces the extent of permanent brain injury in survivors Epidemiologic studies
      estimate the incidence of viral encephalitis at 3.5 to 7.4 per 100,000 persons per year.
      Overall, viruses are the most common cause of encephalitis.

      The Centers for Disease Control and Prevention (CDC) estimates an annual incidence of
      approximately 20,000 new cases of encephalitis in the United States; most are mild in nature.
      The mortality depends largely on the etiologic agent of the encephalitis.

      Herpes simplex virus (HSV) encephalitis (HSVE) is the most common cause of sporadic
      encephalitis in humans. More than 90% of HSVE cases are attributable to HSV type-1 (HSV-1).
      Approximately 5% of them are caused by HSV type-2 HSVE is a severe disease, often leading to
      high morbidity (40%) and mortality (up to 15% in treated cases and 70% in untreated cases)
      Patients with encephalitis have an altered mental status ranging from subtle deficits to
      complete unresponsiveness. The typical clinical presentation includes a rapid onset of fever
      and impaired consciousness, often accompanied by focal neurologic signs and seizures.

      The current treatment of choice is the viral replication inhibitor acyclovir. Although highly
      effective in reducing mortality, it only results in complete recovery in one-half of patients
      . Steroid therapy as an adjunctive therapy in HSVE has good anti inflammatory effect. Steroid
      therapy has both anti inflammatory and immunosuppressive property.

      The diagnosis of viral encephalitis is suspected in the context of a febrile disease
      accompanied by headache, altered level of consciousness, and symptoms and signs of cerebral
      dysfunction. These may consist of abnormalities that can be categorized into four: cognitive
      dysfunction (acute memory disturbances), behavioural changes (disorientation, hallucinations,
      psychosis, personality changes, agitation), focal neurological abnormalities (such as
      anosmia, dysphasia, hemiparesis, hemianopia etc.) and seizures. After the diagnosis is
      suspected, the approach should consist of obtaining a meticulous history and a careful
      general and neurological examination.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conscious level</measure>
    <time_frame>5 days</time_frame>
    <description>Glasgow coma scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Encephalitis, Viral</condition>
  <arm_group>
    <arm_group_label>Patients will receive steroid pulse therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients will receive low dose steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>30mg per kg per day for 5 days followed by course of oral prednisolone</description>
    <arm_group_label>Patients will receive steroid pulse therapy</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>0.6mg per kg perday for 5 days</description>
    <arm_group_label>Patients will receive low dose steroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients who attending Neurology unit in Assiut University Children Hospital
             and diagnosed as viral encephalitis.

          -  Age 1month : 18 year .

          -  Both sexes.

          -  Diagnosis of viral encephalitis will be confirmed by clinical picture ,investigations
             and exclusion of other causes of encephalopathy

        Exclusion Criteria:

          -  Autoimmune encephalitis

          -  Renal failure (any patient with abnormal renal function tests will be excluded)

          -  Hepatic failure ( any patient with abnormal liver function tests will be excluded)

          -  Metabolic disorders (any patient with abnormal level of ammonia and lactate )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gamal Ali, Professor</last_name>
    <phone>01111686162</phone>
    <email>gamal.asker@med.au.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasser Farouk, Lecturer</last_name>
    <phone>01111168123</phone>
    <email>yasser.resk@med.au.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>Hjalmarsson A, Blomqvist P, Sk√∂ldenberg B. Herpes simplex encephalitis in Sweden, 1990-2001: incidence, morbidity, and mortality. Clin Infect Dis. 2007 Oct 1;45(7):875-80. Epub 2007 Aug 24.</citation>
    <PMID>17806053</PMID>
  </reference>
  <reference>
    <citation>Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, Kennedy PG. Viral encephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol. 2005 May;12(5):331-43. Review.</citation>
    <PMID>15804262</PMID>
  </reference>
  <reference>
    <citation>Raschilas F, Wolff M, Delatour F, Chaffaut C, De Broucker T, Chevret S, Lebon P, Canton P, Rozenberg F. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis. 2002 Aug 1;35(3):254-60. Epub 2002 Jul 10.</citation>
    <PMID>12115090</PMID>
  </reference>
  <reference>
    <citation>Mailles A, Stahl JP; Steering Committee and Investigators Group. Infectious encephalitis in france in 2007: a national prospective study. Clin Infect Dis. 2009 Dec 15;49(12):1838-47. doi: 10.1086/648419.</citation>
    <PMID>19929384</PMID>
  </reference>
  <reference>
    <citation>McGrath N, Anderson NE, Croxson MC, Powell KF. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J Neurol Neurosurg Psychiatry. 1997 Sep;63(3):321-6.</citation>
    <PMID>9328248</PMID>
  </reference>
  <reference>
    <citation>Whitley RJ. Viral encephalitis. N Engl J Med. 1990 Jul 26;323(4):242-50. Review.</citation>
    <PMID>2195341</PMID>
  </reference>
  <reference>
    <citation>Gordon B, Selnes OA, Hart J Jr, Hanley DF, Whitley RJ. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol. 1990 Jun;47(6):646-7.</citation>
    <PMID>2346392</PMID>
  </reference>
  <reference>
    <citation>Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, Hartman BJ, Kaplan SL, Scheld WM, Whitley RJ; Infectious Diseases Society of America. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008 Aug 1;47(3):303-27. doi: 10.1086/589747.</citation>
    <PMID>18582201</PMID>
  </reference>
  <reference>
    <citation>Solomon T, Michael BD, Smith PE, Sanderson F, Davies NW, Hart IJ, Holland M, Easton A, Buckley C, Kneen R, Beeching NJ; National Encephalitis Guidelines Development and Stakeholder Groups. Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012 Apr;64(4):347-73. doi: 10.1016/j.jinf.2011.11.014. Epub 2011 Nov 18.</citation>
    <PMID>22120595</PMID>
  </reference>
  <reference>
    <citation>Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, Kennedy PG. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol. 2010 Aug;17(8):999-e57. doi: 10.1111/j.1468-1331.2010.02970.x. Epub 2010 Mar 3. Review.</citation>
    <PMID>20236175</PMID>
  </reference>
  <reference>
    <citation>Ramos-Estebanez C, Lizarraga KJ, Merenda A. A systematic review on the role of adjunctive corticosteroids in herpes simplex virus encephalitis: is timing critical for safety and efficacy? Antivir Ther. 2014;19(2):133-9. doi: 10.3851/IMP2683. Epub 2013 Sep 6. Review.</citation>
    <PMID>24009096</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>AA Nagy</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Viral</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

